Page last updated: 2024-12-06

diacetolol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

diacetolol: RN given refers to parent cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID50894
CHEMBL ID2110821
SCHEMBL ID828479
MeSH IDM0084991

Synonyms (45)

Synonym
acetanilide, 3'-acetyl-4'-(2-hydroxy-3-(isopropylamino)propoxy)-, dl-
einecs 245-088-3
(1)-n-(3-acetyl-4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)acetamide
brn 2156350
diacetololum [inn-latin]
diacetolol
m and b 16942
diacetolol [inn:ban]
acetylacebutolol
acetamide, n-(3-acetyl-4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)-, (+-)-
(+-)-diacetolol
(+-)-n-(3-acetyl-4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)acetamide
dl-1-(2-acetyl-4-acetamidophenoxy)-2-hydroxy-3-isopropylaminopropane
(rs)-1-(2-acetyl-4-acetamidophenoxy)-2-hydroxy-3-isopropylaminopropane
FT-0666315
n-[3-acetyl-4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide
28197-69-5
unii-4er0cz5g7c
22568-64-5
4er0cz5g7c ,
diacetololum
rac diacetolol
(+/-)-3'-acetyl-4'-(2-hydroxy-3-(isopropylamino)propoxy)acetanilide
diacetolol [inn]
diacetolol [who-dd]
acebutolol hydrochloride impurity b [ep impurity]
n-(3-acetyl-4-((2rs)-2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)acetamide
n-(3-acetyl-4-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide
acetamide, n-(3-acetyl-4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)-, (+/-)-
SCHEMBL828479
CHEMBL2110821
AKOS027288882
n-(3-acetyl-4-(2-hydroxy-3-(isopropylamino)-propoxy)phenyl)acetamide
Q5270217
E76509
(+/-)-n-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]acetamide
acetamide,n-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]-,(?-
acebutolol impurity b
(+/-)-diacetolol
DTXSID70865421
CS-0019867
n-(3-acetyl-4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)acetamide
EN300-18166916
Z2037280151
HY-100635

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Acebutolol is as effective as other beta-blocking agents, and in a large, double-blind, parallel study against propranolol was found to cause less reduction in heart rate, and fewer neurologic side effects and patient withdrawals due to adverse effects."( Acebutolol: a review of its pharmacology, pharmacokinetics, clinical uses, and adverse effects.
Singh, BN; Thoden, WR; Wahl, J,
)
0.13

Pharmacokinetics

ExcerptReferenceRelevance
" Furthermore, the effect of cimetidine (CIM) on pharmacokinetic parameters of AC and its metabolite diacetolol (DC) was evaluated."( Influence of cimetidine co-administration on the pharmacokinetics of acebutolol enantiomers and its metabolite diacetolol in a rat model: the effect of gastric pH on double-peak phenomena.
Foster, RT; Mostafavi, SA, 2003
)
0.75

Bioavailability

ExcerptReferenceRelevance
"The pharmacokinetics and bioavailability of diacetolol, the principal metabolite of acebutolol, were studied in 6 healthy subjects."( Pharmacokinetics and bioavailability of diacetolol, the main metabolite of acebutolol.
Andre-Fouet, X; Chau, NP; Flouvat, B; Gregoire, J; Roux, A; Viallet, M; Woehrle, R, 1981
)
0.79

Dosage Studied

ExcerptRelevanceReference
" Evaluation of the iatrogenic risk shows that pharmacologically active amounts of acebutolol might be received by a neonate if the daily maternal dosage exceeds 400 mg/day and/or renal function in the mother is impaired."( To nurse when receiving acebutolol: is it dangerous for the neonate?
Bianchetti, G; Boutroy, MJ; Dubruc, C; Morselli, PL; Vert, P, 1986
)
0.27
" When applied to the assay of biological fluids collected during single and chronic oral dosing with acebutolol (Sectral), this procedure failed to reveal any important stereoselectivity in the disposition of either acebutolol or diacetolol in man."( Preliminary study of the disposition in man of acebutolol and its metabolite, diacetolol, using a new stereoselective hplc method.
Gulaid, A; Kaye, CM; Sankey, MG, 1984
)
0.68
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1147037Antiarrhythmic activity in iv dosed dog assessed as dose required for reversal of ouabain-induced cardiac arrhythmia1976Journal of medicinal chemistry, Mar, Volume: 19, Issue:3
A new series of cardioselective adrenergic beta-receptor blocking compounds. 1-(2-Acyl-4-acylaminophenoxy)-3-isopropylaminopropan-2-ols.
AID1147034In vivo beta-1 adrenergic receptor blocking activity in iv dosed cat assessed as half dose required for desensitizing isoproterenol-induced tachycardia after 3.5 mins1976Journal of medicinal chemistry, Mar, Volume: 19, Issue:3
A new series of cardioselective adrenergic beta-receptor blocking compounds. 1-(2-Acyl-4-acylaminophenoxy)-3-isopropylaminopropan-2-ols.
AID1147036Ratio of in vivo beta-2 adrenergic receptor blocking activity in iv dosed cat assessed as half dose required for desensitizing isoproterenol-induced diastolic hypotensive response to in vivo beta-1 adrenergic receptor blocking activity in iv dosed cat ass1976Journal of medicinal chemistry, Mar, Volume: 19, Issue:3
A new series of cardioselective adrenergic beta-receptor blocking compounds. 1-(2-Acyl-4-acylaminophenoxy)-3-isopropylaminopropan-2-ols.
AID1147035In vivo beta-2 adrenergic receptor blocking activity in iv dosed cat assessed as half dose required for desensitizing isoproterenol-induced diastolic hypotensive response after 3.5 mins1976Journal of medicinal chemistry, Mar, Volume: 19, Issue:3
A new series of cardioselective adrenergic beta-receptor blocking compounds. 1-(2-Acyl-4-acylaminophenoxy)-3-isopropylaminopropan-2-ols.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (40)

TimeframeStudies, This Drug (%)All Drugs %
pre-199028 (70.00)18.7374
1990's6 (15.00)18.2507
2000's4 (10.00)29.6817
2010's1 (2.50)24.3611
2020's1 (2.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.69 (24.57)
Research Supply Index4.03 (2.92)
Research Growth Index4.13 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials9 (19.57%)5.53%
Reviews2 (4.35%)6.00%
Case Studies1 (2.17%)4.05%
Observational0 (0.00%)0.25%
Other34 (73.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]